ARTICLES BY THIS AUTHOR
- 3/16/2021
Fruth Pharmacy launches medication safety, disposal campaign
Fruth Pharmacy, The West Virginia Drug Intervention Institute and DisposeRx are collaborating on a medication safety and disposal campaign that will run through June 30. - 3/16/2021
Hy-Vee, Hormel Foods to give away 5K hams
The Fourth Annual Hams for the Holidays initiative includes stops in 14 cities this month where Hy-Vee employees, alongside local law enforcement, fire and EMS first responders, will hand out 5,000 Hormel Cure 81 hams to families in need. - 3/16/2021
Amazon to widen Amazon Care service availability
Amazon will reportedly roll out its on-demand healthcare service, Amazon Care, across the nation beginning this summer. - 3/16/2021
Several community pharmacies earn NCPA Innovation Center Excellence Award
The National Community Pharmacists Association’s Innovation Center Excellence Award recognizes pharmacies for their efforts to enhance value, promote services and better serve communities. - 3/16/2021
Sandoz obtains distribution rights for Proventil HFA generic
With the commercial distribution rights to the brand and authorized generic of Proventil HFA, Sandoz is expanding its respiratory portfolio. - 3/16/2021
McKesson augments integrated pharmacy services for specialty clinics
McKesson’s health system clients will be offered VHRxS’ full suite of specialty pharmacy consulting services. - 3/15/2021
Cipla wins FDA OK for generic Imitrex
Imitrex Nasal Spray and its generic equivalents had a market value of approximately $53.3 million for the 12 months ended December 2020, according to IQVIA. - 3/15/2021
CVS Health’s transformation leader to take top job at Ontrak
Jonathan Maythew, is departing his role as CVS Health’s chief transformation officer to become CEO of virtual healthcare company Ontrak. - 3/15/2021
Zydus Cadila receives FDA nod for generic Pamelor
Zydus Cadila's generic Pamelor is indicated to treat such mental/mood problems as depression. - 3/15/2021
Lannett’s development of biosimilar Lantus advances with FDA feedback
Lannett expects to start a pivotal trial for its biosimilar Lantus early in 2022, with expectations of a launch in 2023.